MedTrace Logo

A Clinical Risk Score to Stratify High-risk PanNETs

NCT07695532 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 552

Last updated 2026-07-10

No results posted yet for this study

Summary

Considerable heterogeneity exists in the risk of recurrence after curative resection of pancreatic neuroendocrine tumors (PanNETs). Current clinicopathological parameters (e.g., grade, TNM stage) have limited capacity for individualized risk stratification. There is an urgent need for a clinically accessible and operationally simple predictive tools to identify high-risk PanNETs for optimizing personalized postoperative treatment and follow-up strategies. This study aims to identify risk factors associated with recurrence of PanNETs and to develop a clinically applicable risk stratification tool based on multi-center cohorts and multi-omics validation for identifying high-risk patients.

Conditions

  • Pancreatic Neuroendocrine Tumors

Interventions

PROCEDURE

Curative surgical resection

After pathological confirmation of pancreatic neuroendocrine neoplasm, the patient underwent radical surgery.

Sponsors & Collaborators

  • West China Hospital

    collaborator OTHER

  • IRCCS San Raffaele

    collaborator OTHER

  • Fudan University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2026-07-01
Completion
2026-07-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07695532 on ClinicalTrials.gov